Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post Authorization Study, Designed to Learn More About the Safety and Efficacy of the Use of VELCADE (Bortezomib) in the Netherlands

NCT00440765 is registered in ClinicalTrials.gov with Janssen-Cilag B.V. as lead sponsor.

NCT NCT00440765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00440765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post Authorization Study, Designed to Learn More About the Safety and Efficacy of the Use of VELCADE (Bortezomib) in the Netherlands
Lead sponsor
Janssen-Cilag B.V.
Phase
Observational
Overall status
Completed
Start date
November 30, 2004
Completion date
January 31, 2012
Enrollment
331 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

hematological neoplasms, multiple myeloma